Spasticity Epidemiology Summary
Spasticity Insights and Trends
- According to DelveInsight’s analysis, the Spasticity market in the 7MM is expected to grow steadily during the forecast period, supported by improved diagnosis and treatment rates, increasing access to specialized rehabilitation services, and the emergence of innovative therapies aimed at providing longer-lasting symptom control and enhanced functional outcomes.
- Spasticity may occur due to several conditions, including: Spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head injury, Amyotrophic Lateral Sclerosis (ALS), hereditary spastic paraplegias, Adrenoleukodystrophy (ALD), phenylketonuria, and Krabbe disease.
- Spasticity affects 43% of the stroke patients at 12 months after onset.
- Spasticity is a common symptom in children with cerebral palsy, affecting about 80% of these children. It can also occur in children with traumatic brain injuries, strokes, infections, genetic conditions, and other neurological disorders.
- Women are more likely to develop spasticity due to conditions like multiple sclerosis, which is more common in women. Spasticity can significantly impact daily activities, mobility, and overall quality of life. Women with spasticity may face unique challenges, including managing household responsibilities and caregiving roles. Treatment approaches for spasticity do not differ significantly between genders.
Electrical stimulation of the spinal cord is a promising strategy for reestablishing walking after spinal cord injury. But for patients suffering from muscle spasms, the stimulation protocols have a limited effect due to the unpredictable behaviour of involuntary muscle stiffness related to spasticity.
Spasticity Epidemiology Forecast in the 7MM
- 2025 Diagnosed Prevalent Cases of Spasticity: ~ USD XX million
- Spasticity Growth Rate (2026–2036): ~XX % CAGR
DelveInsight's ‘Spasticity – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Spasticity, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2026 |
|
Geographies Covered |
|
|
Spasticity Epidemiology CAGR (Study period/Forecast period) |
~XX % (2026–2036) |
|
Spasticity Epidemiology Segmentation Analysis |
Patient Burden Assesment
|
Spasticity Understanding and Diagnostic Algorithm
Spasticity Overview and Diagnosis
Spasticity is a neurological disorder characterized by increased muscle tone, stiffness, and involuntary muscle spasms resulting from damage to the brain or spinal cord. It commonly occurs in conditions such as multiple sclerosis, cerebral palsy, stroke, traumatic brain injury, and spinal cord injury, leading to impaired mobility, pain, and reduced quality of life. Diagnosis is primarily based on clinical neurological examination using assessment tools such as the Modified Ashworth Scale (MAS) and Tardieu Scale, supported by imaging techniques like MRI or CT scans when necessary. Management involves a multidisciplinary approach, including physical therapy, oral antispastic agents, botulinum toxin injections, and intrathecal therapies, with emerging treatments aiming to improve long-term functional outcomes.
Further details are provided in the report.
Spasticity Epidemiology
Key Findings from Spasticity Epidemiological Analysis and Forecast
- Spasticity affects approximately 35% of those with stroke, more than 90% with cerebral palsy, about 50% of traumatic brain injury patients, 40% of spinal cord injury patients, and between 37% and 78% of multiple sclerosis patients.
- According to the National Multiple Sclerosis Society (2024), out of the 1,177 adults with multiple sclerosis, 80% of respondents reported that they experienced spasticity every day, or multiple times each day, and 34% had constant spasticity symptoms. Spasticity was mostly considered to be moderate to severe.
- In adults, approximately one in three stroke patients, one in three patients with spinal cord injury, one in six patients with traumatic brain injury, and two in three patients with multiple sclerosis will develop lower limb spasticity.
- In the United Kingdom, 82% experience spasticity and 54% classified the impact of spasticity as “moderate”. Greater than 80% of patients with multiple sclerosis report some degree of spasticity, with one third of these modifying or eliminating daily activities as a result.
Scope of the Report
- The report covers a segment of an executive summary, a descriptive overview of spasticity, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- Spasticity Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (epi‑based) Bottom‑up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs
- What are the disease risks, burdens, and unmet needs of Spasticity? What will be the growth opportunities across the 7MM concerning the patient population with Spasticity?
- What is the historical and forecasted Spasticity patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
